Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor (IC50 values are 15 and 0.04 μM for COX-1 and COX-2 respectively). Celecoxib is an anti-inflammatory with shorter plasma half-life in vivo than SC 58121. Displays chemopreventive activity in in vivo tumor models.
Celecoxib is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen Antiviral Library. Find out more about compound libraries available from Tocris.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 381.37. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||5.24 mL||26.22 mL||52.44 mL|
|2.5 mM||1.05 mL||5.24 mL||10.49 mL|
|5 mM||0.52 mL||2.62 mL||5.24 mL|
|25 mM||0.1 mL||0.52 mL||1.05 mL|
References are publications that support the biological activity of the product.
Penning et al (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J.Med.Chem. 40 1347 PMID: 9135032
DeWitt (1999) Cox-2-selective Inhibitors: the new super aspirins. Mol.Pharmacol. 55 625 PMID: 10101019
Harris et al (2000) Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 60 2101 PMID: 10786667
If you know of a relevant reference for Celecoxib, please let us know.
Keywords: Celecoxib, Celecoxib supplier, Selective, cyclooxygenase-2, COX-2, inhibitors, inhibits, Oxygenases, Oxidases, SC58635, prostaglandins, SC, 58635, Celebrex, Cyclooxygenase, 3786, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for Celecoxib include:
Bowler et al (2019) CXB Is Associated With Dystrophic Calcification and Aortic Valve Stenosis. JACC Basic Transl Sci 4 135 PMID: 31061914
Oguh-Olayinka et al (2019) The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma. Pathol Oncol Res PMID: 30941737
Do you know of a great paper that uses Celecoxib from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review Celecoxib and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.